Mr Clément Orczyk is a Clinical Academic, Consultant Urologist, and Clinical Lead of the Prostate Cancer Unit for diagnostics, active surveillance, and focal therapy at University College London Hospitals (UCLH). He also holds a tenure position as an Associate Professor of Urology at University College London (UCL). Clément integrates innovation within his research and clinical practice, firmly believing in the interconnectedness of these fields to provide highest and above standard care patient care. His commitment to excellence in research and clinical care, particularly in the imaging and focal therapy of prostate cancer, has taken him from his native France to the United States, where he completed a fellowship at New York University in 2011, and subsequently to UCL. He has been a Consultant at UCLH since 2017.

Mr Orczyk developed his expertise in prostate cancer during the early stages of a paradigm shift focused on detecting and treating the disease using the most advanced imaging techniques in conjunction with tissue analysis. He earned a PhD on this subject from a renowned French research center in collaboration with NYU. He authored the first publication establishing the necessary 3D margins for focal therapy to eradicate the whole cancer detected through imaging, thereby minimizing treatment side effects while maximizing the therapeutic outcomes of these innovative approaches. In his routine practice, Mr Orczyk delivers focal therapy to carefully selected patients using modalities such as focal High Intensity Focused Ultrasound (HIFU), focal cryotherapy, and Nanoknife electroporation. As one of the few clinicians globally proficient in multiple forms of ablation, he is uniquely positioned to select the most appropriate focal energy for optimal patient outcomes. He has performed over 700 focal therapy procedures using these techniques, in addition to those conducted within cutting-edge clinical trials involving new technologies. 

Dedicated to individualized diagnosis, Mr Orczyk adapts MRI and imaging findings to prostate biopsy, aiming to reduce their invasiveness while maximizing the information obtained for further disease stratification. He continues to advance his translational research program in prostate cancer detection, combining imaging, molecular biology, and more recently, Artificial Intelligence, with the goal of detecting only clinically significant disease for each patient. He is also exploring new approaches to cancer treatment. Clément is a sought-after speaker at major international conferences, publishes in high-impact journals, and is committed to training both current and future generations of clinicians. With his expertise in healthcare systems, innovation, and science, Mr Orczyk seeks to contribute to Franco-British relations at a higher level as an appointee within the Young Leader Program of the Franco-British Council, supported by both the UK and French embassies and governments.